Hutchison China MediTech Ltd. (HCM)
Stock Price Chart
Key Info
| Market Cap | 4.31B |
| Revenue (ttm) | 204.89M |
| Net Income (ttm) | -106.02M |
| Shares Out | 142.16M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 21, 2020 |
| Last Price | $30.32 |
| Previous Close | $30.48 |
| Change ($) | -0.17 |
| Change (%) | -0.54% |
| Day's Open | 30.50 |
| Day's Range | 30.24 - 30.68 |
| Day's Volume | 33,210 |
| 52-Week Range | 14.74 - 34.90 |
More Stats
| Market Cap | 4.31B |
| Enterprise Value | 4.13B |
| Earnings Date (est) | Mar 15, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 142.16M |
| Float | 138.16M |
| EPS (basic) | -0.80 |
| EPS (diluted) | -0.82 |
| FCF / Share | -0.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.02M |
| Short Ratio | 4.06 |
| Short % of Float | 0.74% |
| Beta | 1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 21.03 |
| PB Ratio | 13.23 |
| Revenue | 204.89M |
| Operating Income | -146.39M |
| Net Income | -106.02M |
| Free Cash Flow | -89.48M |
| Net Cash | 184.09M |
| Net Cash / Share | 1.29 |
| Gross Margin | -44.62% |
| Operating Margin | -71.45% |
| Profit Margin | -51.70% |
| FCF Margin | -43.67% |
| ROA | -18.68% |
| ROE | -29.31% |
| ROIC | -31.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 205 | 214 | 241 | 216 | 178 | 87.33 | 36.55 |
| Revenue Growth | -4.31% | -11.23% | 11.63% | 21.25% | 104.06% | 138.95% | - |
| Gross Profit | 44.74 | 70.17 | 65.38 | 59.75 | 67.43 | 28.48 | 25.35 |
| Operating Income | -146 | -92.64 | -53.42 | -46.70 | -9.77 | -18.26 | -13.20 |
| Net Income | -106 | -74.81 | -26.74 | 11.70 | 7.99 | -7.31 | 23.94 |
| Shares Outstanding | 666 | 664 | 617 | 597 | 547 | 526 | 521 |
| Earnings Per Share | -0.80 | -0.55 | -0.20 | 0.10 | -0.32 | -0.31 | 0.21 |
| Operating Cash Flow | -80.91 | -32.85 | -8.94 | -9.57 | -9.39 | 8.36 | 5.03 |
| Capital Expenditures | -8.57 | -6.36 | -5.02 | -4.33 | -3.32 | -3.73 | -2.50 |
| Free Cash Flow | -89.48 | -39.21 | -13.96 | -13.90 | -12.71 | 4.63 | 2.53 |
| Cash & Equivalents | 217 | 301 | 358 | 104 | 31.94 | 51.13 | - |
| Total Debt | 33.08 | 26.74 | 29.99 | 46.79 | 49.85 | 53.21 | - |
| Net Cash / Debt | 184 | 274 | 328 | 56.91 | -17.90 | -2.08 | - |
| Assets | 465 | 532 | 598 | 342 | 230 | 211 | - |
| Liabilities | 152 | 120 | 113 | 138 | 127 | 113 | - |
| Book Value | 288 | 389 | 462 | 184 | 83.36 | 39.15 | - |
Company Profile
Company Details
| Full Name | Hutchison China MediTech Ltd. |
| Country | Hong Kong |
| Employees | 853 |
| CEO | Christian Hogg |
Stock Information
| Ticker Symbol | HCM |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: HCM |
Description
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.